Karyopharm Therapeutics (KPTI) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Agriculture Climate Climate Change Environment Environmental Forest Hazard Intensity Life Cycle Lifecycle Materials Natural Resources Nature Nuclear Offset Package Packaging Pandemic Raw Materials Recycling Regenerative Resiliency Toxic Waste Access Affordability Asian Attrition Benefits Black California Consumer Privacy Act Charitable Charity Collective Bargaining Community Culture Customer Cyber Cybersecurity Data Privacy Data Security Death Demographic Disability Diversity Diversity and Inclusion Drug Pricing Employee Employee Engagement Employee Retention Engagement Ethnic Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Human Capital Human Resources Incident Injuries Injury Minority Pay for Performance Perquisites Privacy Product Quality Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skilled Skills Social Societal Society Stakeholder Supplier Supply Chain Talent Training Union Women Workers Workforce Anti-corruption Assessment Assurance Attorneys General Audit Bonus Bribery Chronic Classified Classified Board Clawback Commitment Committee Evaluation Conflict of Interest Corporate Governance Corruption Department of ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Independence Independent Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Mission Overboarding Oversee Oversight Perquisite Plaintiff Pledging Poison Pill Purpose Quality Standard R&D Recoup Reputation Reputational Reputational Risk Research and Development Responsibility Responsible Self-evaluation Strategy Sustainability Targets Tax Tax Gross Up Tenure Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

Karyopharm Therapeutics Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders on May 21, 2021 (the “Annual Meeting”). The following is a summary of the matters voted on at the Annual Meeting.

The Company’s stockholders elected Deepika Pakianathan, Ph.D., Richard Paulson, M.B.A. and Chen Schor, M.B.A., C.P.A. as Class II directors, each to serve on the board of directors of the Company for a three-year term until the 2024 annual meeting of stockholders and until their resignation or removal or until their successors are duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows:



Deepika Pakianathan, Ph.D.	33,788,086	7,286,491	19,059,473
Richard Paulson, M.B.A.	38,108,285	2,966,292	19,059,473
Chen Schor, M.B.A., C.P.A.	38,165,000	2,909,577	19,059,473

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s proxy statement for the Annual Meeting. The results of the stockholders’ vote with respect to such approval were as follows:

Votes For		Votes Against		Votes Abstaining		Broker Non-Votes

37,981,962		2,969,679		122,936		19,059,473

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The results of the stockholders’ vote with respect to such ratification were as follows:


Votes For	Votes Against	Votes Abstaining
56,309,791	902,442	2,921,817